In this episode of First Assist: GU Oncology Unpacked, host Taylor Goodstein, MD, speaks with Eric A. Singer, MD, MA, MS, FACS, FASCO, The Dave Longaberger Endowed Chair in Urology, professor of urology and bioethics, chief of the urologic oncology, and director of the Urologic Oncology Fellowship Program at The Ohio State University in Columbus about how historical milestones in genitourinary oncology; specifically, kidney cancer, have shaped current practice. Singer traces the evolution of kidney cancer management from the era of radical surgery to today’s precision approaches, highlighting how improved imaging, minimally invasive techniques, and molecular insights have transformed treatment. He underscores the shift from one-size-fits-all surgery toward tailored strategies that balance oncologic control with preservation of renal function and quality of life. The discussion also explores the arc of immunotherapy in urologic cancers—from early cytokine-based regimens to the immune checkpoint inhibitors now embedded in standard care. Singer reflects on how clinical trial design, patient selection, and biomarker research are driving more individualized therapy choices. Throughout the conversation, Goodstein emphasizes the value of understanding the past to better interpret the present and anticipate the future. The two also address how a deeper appreciation for the history of GU oncology can help trainees navigate today’s rapidly expanding knowledge base without losing sight of core principles. Looking ahead, Singer points to ongoing challenges, including optimizing multidisciplinary collaboration, improving trial access for diverse patient populations, and integrating novel therapies in ways that are both evidence-based and patient-centered. His take-home message: progress in GU oncology is built on decades of incremental advances, and the next wave of breakthroughs will require the same blend of innovation, rigorous science, and thoughtful application. Chapters 1:30 Where does the story of kidney cancer treatment begin? 6:54 The strengths and limitations of IL-2 17:40 Comparing mTOR inhibitors and TKIs 25:38 Cytoreductive nephrectomy 36:00 First-line regimens 45:09 Upcoming trials to watch

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related